Mechanisms of bromodomain and extra-terminal motif inhibitor (BETi) sensitivity in triple-negative breast cancer (TNBC)

被引：1
|
作者：
Schafer, Johanna
Lehmann, Brian
Liu, Phillip
Stubbs, Matthew
Scherle, Peggy
Pietenpol, Jennifer
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1518
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer
    Schafer, Johanna M.
    Lehmann, Brian D.
    Redman, Lindsay N.
    Liu, Phillip
    Stubbs, Matthew
    Ruggeri, Bruce
    Scherle, Peggy
    Pietenpol, Jennifer A.
    CANCER RESEARCH, 2018, 78 (04)
  • [2] Therapeutic targeting of bromodomain and extra-terminal proteins degradation in triple-negative breast cancer
    Bai, Longchuan
    Zhou, Bing
    Yang, Chao-Yie
    Ji, Jiao
    McEachern, Donna
    Przybranowski, Sally
    Wang, Shaomeng
    CANCER RESEARCH, 2017, 77
  • [3] Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
    Bian, Benjamin
    Juiz, Natalia Anahi
    Gayet, Odile
    Bigonnet, Martin
    Brandone, Nicolas
    Roques, Julie
    Cros, Jerome
    Wang, Nenghui
    Dusetti, Nelson
    Iovanna, Juan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [4] BET (bromodomain and extra-terminal) histone acetylation readers and histone acetylation in hypoxia adaptation in triple-negative breast cancer
    da Motta, Leonardo L.
    Slater, Charlotte
    Vancauwenberghe, Eric
    Potgieter, Tammy
    Masterson, Mitchell
    Heery, David M.
    McIntyre, Alan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 548 - 548
  • [5] Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells
    Gayle, Sylvia S.
    Sahni, Jennifer M.
    Webb, Bryan M.
    Weber-Bonk, Kristen L.
    Shively, Melyssa S.
    Spina, Raffaella
    Bar, Eli E.
    Summers, Mathew K.
    Keri, Ruth A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (03) : 875 - 886
  • [6] Discovery of a small molecule inhibitor for triple-negative breast cancer (TNBC)
    Saran, Uttara
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Singh, Amandeep
    Ankem, Murali K.
    Sharma, Arun K.
    Damodaran, Chendil
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review
    Tajbakhsh, Amir
    Rivandi, Mandi
    Abedini, Soheila
    Pasdar, Alireza
    Sahebkar, Amirhossein
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 140 : 17 - 27
  • [8] Triple-negative breast cancer (TNBC) phosphoproteomics
    Gaitero, Sara Fernandez
    Zagorac, Ivana
    Lopez-Acosta, Jose Francisco
    Gomez-Lopez, Gonzalo
    Pisano, David Gonzalez
    Peralta, Javier Munoz
    Manso, Luis
    Alonso, Soledad
    Penning, Renske
    Altelaar, Maarten
    Heck, Albert J. R.
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2017, 77
  • [9] Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
    Alqahtani, Ali
    Choucair, Khalil
    Ashraf, Mushtaq
    Hammouda, Danae M.
    Alloghbi, Abduraham
    Khan, Talal
    Senzer, Neil
    Nemunaitis, John
    FUTURE SCIENCE OA, 2019, 5 (03):
  • [10] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
12345